SEARCH

SEARCH BY CITATION

References

  • Auerbach, M. (2007) Intravenous iron. New England Journal of Medicine, 357, 9394.
  • Auerbach, M., Ballard, H., Trout, J.R., Mcilwain, M., Ackerman, A., Bahrain, H., Balan, S., Barker, L. & Rana, J. (2004) Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multi-center, open-label, randomized trial. Journal of Clinical Oncology, 22, 13011307.
  • Bellet, R.E., Ghazal, H., Flam, M., Drelichman, A., Gabrail, D., Woytowitz, D., Loesch, D., Niforos, A., Mangione, L. & Anthonyf or the Iron Sucrose Study Group (2007) A phase III randomized, controlled study comparing iron sucrose intravenously (IV) to no iron treatment of anaemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 9109.
  • Bennett, C.L., Cournoyer, D., Carson, K.R., Rossert, J., Luminari, S., Evens, A.M., Locatelli, F., Belknap, S.M., Mckoy, J.M., Lyons, E.A., Kim, B., Sharma, R., Costello, S., Toffelmire, E.B., Wells, G.A., Messner, H.A., Yarnold, P.R., Trifilio, S.M., Raisch, D.W., Kuzel, T.M., Nissenson, A., Lim, L.C., Tallman, M.S. & Casadevall, N. (2005) Long term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin: a follow-up report from the research on adverse drug events and reports (RADAR). Blood, 106, 33433347.
  • Bokemeyer, C., Aapro, M.S., Courdi, A., Foubert, J., Link, H., Osterborg, A., Repetto, L. & Soubeyran, P. (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. European Journal of Cancer, 43, 258270.
  • Brewster, U.C. (2006) Intravenous iron therapy in end-stage renal disease. Seminars in Dialysis, 19, 285290.
  • Canadian erythropoietin study group (1990) Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. British Medical Journal, 300, 573578.
  • Cavill, I., Auerbach, M., Bailie, G.R., Barrett-Lee, P., Beguin, Y., Kaltwasser, P., Littlewood, T., Macdougall, I.C. & Wilson, K. (2006) Iron and the anaemia of chronic disease: a review and strategic recommendations. Current Medical Research and Opinion, 22, 731737.
  • Chang, J., Couture, F., Young, S., McWatters, K.L. & Lau, C.Y. (2005) Weekly epoetin Alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast Cancer patients receiving chemotherapy. Journal of Clinical Oncology, 23, 25972605.
  • Chertow, G.M., Mason, P.D., Vaage-Nilsen, O. & Ahlmen, J. (2006) Update on adverse events associated with parenteral iron. Nephrology Dialysis and Transplantation, 21, 378382.
  • Drueke, T.B., Locatelli, F., Clyne, N., Eckardt, K.U., Macdougall, I.C., Tsakiris, D., Burger, H.U. & Scherhag, A. (2006) Normalisation of hemoglobin levels in patients with chronic kidney disease and anemia. New England Journal of Medicine, 355, 20712084.
  • Fielding, J. (1977) Does sarcoma occur in man after intramuscular iron? Scandinavian Journal of Haematology. Supplement, 32, 100104.
  • Fishbane, S., Mittal, S.K. & Maesaka, J.K. (1999) Beneficial effects of iron therapy in renal failure patients on hemodialysis. Kidney International Supplement, 55, S67S70.
  • Frankenfield, D.L., Neu, A.M., Warady, B.A., Fivush, B.A., Johnson, C.A. & Brem, A.S. (2003) Anemia in pediatric hemodialysis patients: results from the 2001 ESRD clinical performance measures project. Kidney International, 64, 11201124.
  • Ganz, T. (2006) Hepcidin and its Role in Regulating Systemic Iron Metabolism. Hematology – American Society of Hematology Education Program, 2935.
  • Hamstra, R.D., Block, M.H. & Schocket, A.L. (1980) Intravenous iron dextran in clinical medicine. Journal of the American Medical Association, 243, 17261731.
  • Hedenus, M., Adriansson, M., San Miguel, J., Kramer, M.H.H., Schipperus, M.R., Juvonen, E., Taylor, K., Belch, A., Altés, A., Martinelli, G., Watson, D., Matcham, J., Rossi, G. & Littlewood, T.J. (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies; a randomised, double-blind, placebo controlled study. British Journal of Haematology, 122, 394403.
  • Hedenus, M., Birgegard, G., Nasman, P., Ahlberg, L., Karlsson, T., Lauri, B., Lundin, J., Larfars, G. & Osterborg, A. (2007) Addition of intravenous iron to epoetin beta increases haemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomised multicenter study. Leukemia, 21, 627632.
  • Henke, M., Laszig, R., Rube, C., Schafer, U., Haase, K.D., Schilcher, B., Mose, S., Beer, K.T., Burger, U., Dougherty, C. & Frommhold, H. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet, 362, 12551260.
  • Henry, D.H., Dahl, N.V., Auerbach, M., Tchekmedyian, S. & Laufman, L.R. (2007) Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. The Oncologist, 12, 231242.
  • Hershko, C., Peto, T.E.A. & Weatherall, D.J. (1988) Iron and infection. British Medical Journal, 296, 660664.
  • Kim, Y.T., Kim, S.W., Yoon, B.S., Cho, H.J., Nahm, E.J., Kim, S.H., Kim, J.H. & Kim, J.W. (2007) Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecologic Oncology, 105, 199204.
  • Lerchenmueller, C., Husseini, F., Gaede, B., Mossman, T., Suto, T. & Vandebroek, A. (2006). Intravenous (IV) iron supplementation in patients with chemotherapy-induced anemia (CIA) receiving darbepoetin alfa every 3 weeks (Q3W): iron parameters in a randomized controlled trial. Blood 108; Abstract 1552.
  • Lin, L., Valore, E.V., Nemeth, E., Goodnough, J.B., Gabayan, V. & Ganz, T. (2007) Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood, 110, 21822189.
  • Littlewood, T.J., Bajetta, E., Nortier, J.W., Vercammen, E. & Rapoport, B. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19, 28652874.
  • Locatelli, F. (2004) Revised European Best Practice Gudelines for the management of anaemia in patients with chronic renal failure. Nephrology Dialysis Transplantation, 19(Suppl. 2), ii1ii47.
  • Ludwig, H., Van Belle, S., Barrett-Lee, P., Birgegard, G., Bokemeyer, C., Gascon, P., Kosmidis, P., Krzakowski, M., Nortier, J., Olmi, P., Schneider, M. & Schrijvers, D. (2004) The European cancer anaemia survey (ECAS): a large, multi-national, prospective survey defining the prevalence, incidence and treatment of anaemia in cancer patients. European Journal of Cancer, 40, 22932306.
  • Means, R.T. (1995) Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells, 13, 3237.
  • Oppenheimer, S.J. (2001) Iron and its relation to immunity and infectious disease. Journal of Nutrition, 131, 616S635S.
  • Pinter, T., Mossman, T., Suto, T. & Vansteenkiste, J. (2007) Effects of intravenous (IV) iron supplementation on responses to every- 3-week (q3w) darbepoetin alfa (DA) by baseline haemoglobin in patients (pts) with chemotherapy-induced anemia (CIA). Proceedings of the American Society of Clinical Oncology, 25, 9106.
  • Reveiz, L., Gyte, G.M. & Cuervo, L.G. (2001). Treatments for iron deficiency anaemia in pregnancy. Cochrane Database Systemic Reviews 18; CD003094.
  • Silverstein, S.B. & Rodgers, G.M. (2004) Parenteral iron therapy options. American Journal of Hematology, 76, 7478.
  • Singh, A.K., Szczech, L., Tang, K.L., Barnhart, H., Sapp, S., Wolfson, M. & Reddan, D. (2006a) Correction of anemia with epoetin alfa in chronic kidney disease. New England Journal of Medicine, 355, 20852098.
  • Singh, H., Reed, J., Noble, S., Cangiano, J.L. & Van Wyck, D.B. (2006b) Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. Clinical Journal of the American Society of Nephrology, 1, 475482.
  • Vandebroek, A., Altintas, S., Gaede, B., Smith, K., Yao, B. & Schupp, M. (2006) Darbepoetin alfa administered every 3 weeks with or without parenteral iron in anaemic patients with non-myeloid malignancies receiving chemotherapy: interim results from a randomized, open-label study. Haematologica, 91(Suppl. 1), abstract 0029.
  • Weiss, G. & Goodnough, L.T. (2005) Anemia of chronic disease. New England Journal of Medicine, 352, 10111023.
  • Winearls, C., Oliver, D.O., Pippard, M.J., Reid, C., Downing, M.R. & Cotes, P.M. (1986) Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet, 2, 11751178.
  • Witzig, T.E., Silberstein, P.T., Loprinzi, C.L., Sloan, J.A., Novotny, P.J., Mailliard, J.A., Rowland, K.M., Alberts, S.R., Krook, J.E., Levitt, R. & Morton, R.F. (2005) Phase III, randomised, double blind study of epoetin alfa compared with placebo in anaemic patients receiving chemotherapy. Journal of Clinical Oncology, 23, 26062617.
  • Wright, J.R., Ung, Y.C., Julian, J.A., Pritchard, K.I., Whelan, T.J., Smith, C., Szechtman, B., Roa, W., Mulroy, L., Rudinskas, L., Gagnon, B., Okawara, G.S. & Levine, M.N. (2007) Randomised, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. Journal of Clinical Oncology, 25, 10271032.